recombinant IL-22 (Jetra Therapeutics)

N/A

Report date: 2025/01/26 17:44:01

Base Information

Drug Namerecombinant IL-22 (Jetra Therapeutics)

Drug Alias Nameengineered cell signaling peptide (Jetra Therapeutics)engineered protein therapy (Jetra Therapeutics)Protein Therapy (Jetra Therapeutics)

ClassificationBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionInterleukin-22 agonists

TargetsInterleukin-22

Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseLiver Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New Zealand

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesThe University Of Queensland

China Registration ClassN/A

Develop Information

Active CompaniesJetra Therapeutics Pty Ltd

Inactive CompaniesThe University Of Queensland

Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseLiver Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A